Andilly (FR)
{name}
{subtitle}
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~46 mi. (La Roche-sur-Yon, France, +158 more cities)
facility
CHD Vendee ( Site 0807)
condition
Non-Small Cell Lung Carcinoma
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
city
~46 mi. (La Roche-sur-Yon, France, +115 more cities)
facility
CHD Vendee ( Site 0604)
biomarker
ATM Loss, +27 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib, +1 more drug
drug type
immunotherapy, +1 more type
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
city
~93 mi. (Poitiers, France, +145 more cities)
facility
CHU Poitiers ( Site 1109)
condition
Non-Small Cell Lung Carcinoma
drug
pembrolizumab, +1 more drug
drug type
immunotherapy, +2 more types
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~93 mi. (Poitiers, France, +105 more cities)
facility
CHU Poitiers ( Site 0612)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib
drug type
targeted therapy
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
city
~93 mi. (Poitiers, France, +54 more cities)
facility
CHU Poitier - La milétrie /ID# 229833
condition
Multiple Myeloma
drug
carfilzomib, +4 more drugs
drug type
chemotherapy, +3 more types
Evaluation of Pembrolizumab (MK-3475) or Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)
city
~93 mi. (Poitiers, France, +30 more cities)
facility
Centre Hospitalier Universitaire de Poitiers ( Site 0511)
biomarker
Deficient DNA Mismatch Repair (dMMR), +5 more biomarkers
condition
Colorectal Adenocarcinoma
drug
MK-1308A, +4 more drugs
drug type
immunotherapy